Protection against Omicron BA.1/BA.2 severe disease 0-7 months after BNT162b2 booster.

ABSTRACT: Following evidence of waning immunity against both infection and severe disease after 2 doses of the BNT162b2 vaccine, Israel began administering a 3rd BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the Omicron variant compared to the Delta variant and that this protection wanes quickly. However, there is little evidence regarding the protection of the 3rd dose against Omicron (BA.1/BA.2) severe disease. In this study, we estimate the preservation of immunity from severe disease up to 7 months after receiving the booster dose. We calculate rates of severe SARS-CoV-2 disease between groups of individuals aged 60 and above, comparing those who received two doses at least 4 months previously to those who re

SUBMITTER: Amir O 

PROVIDER: S-EPMC10035472 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature